MedTrace Logo

Substance Misuse To Psychosis for Ketamine (SToP-K)

NCT03485339 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2020-07-31

No results posted yet for this study

Summary

Evidence suggests that repeated or chronic ketamine use, as compared to acute ketamine users, posed a higher clinical risk of developing psychotic disorders, potentially related to the underlying chronic N-methyl-D-aspartate receptor (NMDAR) dysfunction, and a higher risk of suffering from schizophrenia particularly in those genetically susceptible, or genetically predisposed ketamine abusers. With ketamine infusion rises as a emerging hope as an acute treatment for depression and suicidality under the shadow of unknown longer term psychotomimetic effects peculiarly amongst repeated or chronic use, the current case-control study aims to investigate: a) if repeated or chronic ketamine use is associated with an increased risk of psychosis by comparing those ketamine abusers with and without psychosis, and to those non-ketamine-using drug abusers with psychosis; and b) if genetic predisposition from single nucleotide polymorphisms are associated with risk of psychosis in ketamine abusers.

Conditions

Interventions

DIAGNOSTIC_TEST

genome testing

blood sampling via venipuncture

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • albert KK Chung, MBBS(HK) · The University of Hong Kong

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2020-03-01
Completion
2020-04-01

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485339 on ClinicalTrials.gov